CoChat

Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy

Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., Shalet, S. M. · 2001 · Clinical Endocrinology
Cited by 116

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

OBJECTIVE Testosterone deficiency is associated with significant morbidity, and androgen replacement in overt hypogonadism is clearly beneficial. However, there are few data concerning the response to therapy in young men with mild testosterone deficiency. DESIGN AND PATIENTS We have identified a cohort of 35 men, mean age 40·9 years, with mild Leydig cell dysfunction, defined by a raised LH level (LH ≥ 8 IU/l) and a testosterone level in the lower half of the normal range or frankly subnormal (testosterone < 20 nmol/l), following treatment with cytotoxic chemotherapy for malignancy. Patients were assigned randomly to 12 months treatment with transdermal testosterone (n = 16) (Andropatch 2·5 mg patches, 1–2 patches per day) or placebo patches (n = 19) in a single blinded manner. MEASUREMENTS Measurements of bone mineral density (BMD) and body composition were performed at baseline, 6 months and 12 months using single and dual energy X‐ray absorptiometry (SXA, DXA). In addition, spinal BMD was assessed at baseline and 12 months by quantitative CT (QCT). Subjects were reviewed at 3‐monthly intervals; at each visit blood was taken for measurement of testosterone, SHBG, LH, FSH, oestradiol, lipids and IGF‐1 and patients completed three questionnaires which assessed energy levels, mood and sexual function. RESULTS Total testosterone and calculated free testosterone increased significantly in the testosterone‐treated group compared with the placebo‐treated group (13·3 nmol/l and 342·9 pmol/l at baseline compared with 17·3 nmol/l and 454·8 pmol/l during the study period in the testosterone‐treated group; P = 0·05 and P = 0·02, respectively). LH was suppressed into the normal range in 15 of the 16 testosterone‐treated men and mean LH significantly reduced from 11·1 IU/l at baseline to 6·8 IU/l during the study. There was no significant change in BMD at the hip, spine or forearm and no change in fat or lean body mass. There was a significant reduction in physical fatigue in the testosterone‐treated group compared with the placebo‐treated group (P = 0·008) and a borderline improvement in activity score (P = 0·05). There were no significant effects of treatment on mood or sexual function. Neither oestradiol nor IGF‐1 levels differed between the two groups during the study. There was no significant change in mean total cholesterol, HDL cholesterol or triglyceride levels, but there was a small, but significant reduction in LDL cholesterol levels in the testosterone‐treated group compared with the placebo group (P = 0·02). CONCLUSIONS These results suggest that testosterone therapy in young men with raised LH levels and low/normal testosterone levels does not result in significant changes in BMD, body composition, lipids or quality of life, apart from a reduction in physical fatigue and a small reduction in LDL cholesterol. This implies that mild hypogonadism defined on this basis is not of clinical importance in the majority of men, and that androgen replacement cannot be recommended for routine use in these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.2001.01297.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 116

Metadata

Authors
Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., & Shalet, S. M.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2001-09
Volume
55
Issue
3
Pages
315-324
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W2109964083
Cited by
116
References
12
FWCI
3.11
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. https://app.cochat.ai/papers/10.1046/j.1365-2265.2001.01297.x
The paper
Howell, S. J., Radford, J. A., Adams, J. E., Smets, E. M. A., Warburton, R., & Shalet, S. M. (2001). Randomized placebo‐controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.2001.01297.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.